|
1
|
Mattie M, Christensen A, Chang MS, Yeh W,
Said S, Shostak Y, Capo L, Verlinsky A, An Z, Joseph I, et al:
Molecular characterization of patient-derived human pancreatic
tumor xenograft models for preclinical and translational
development of cancer therapeutic. Neoplasia. 15:1138–1150. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sohal DP, Mangu PB, Khorana AA, Shah MA,
Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH,
Engebretson A, et al: Metastatic pancreatic cancer: American
society of clinical oncology clinical practice guideline. J Clin
Oncol. 34:2784–2796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative -intent resection of pancreatic
cancer: A randomized controlled trial. JAMA. 297:267–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang L, Holtzinger A, Jagan I, BeGora M,
Lohse I, Ngai N, Nostro C, Wang R, Muthuswamy LB, Crawford HC, et
al: Ductal pancreatic cancer modeling and drug screening using
human pluripotent stem cell- and patient-derived tumor organoids.
Nat Med. 21:1364–1371. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iguchi H, Yasuda M, Matsuo T, Sumii T and
Funakoshi A: Clinical features and management of pancreatic cancer
with bone metastases. Nippon Shokakibyo Gakkai Zasshi. 101:872–878.
2004.(In Japanese). PubMed/NCBI
|
|
7
|
Pneumaticos SG, Savidou C, Korres DS and
Chatziioannou SN: Pancreatic cancer's initial presentation: Back
pain due to osteoblastic bone metastasis. Eur J Cancer Care (Engl).
19:137–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boj SF, Hwang CI, Baker LA, Chio II, Engle
DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, et al:
Organoid models of human and mouse ductal pancreatic cancer. Cell.
160:324–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heestand GM and Kurzrock R: Molecular
landscape of pancreatic cancer: Implications for current clinical
trials. Oncotarget. 6:4553–4561. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
The Lancet Oncology: Pancreatic cancer:
Cause for optimism? Lancet Oncol. 17:8452016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aparicio S, Hidalgo M and Kung AL:
Examining the utility of patient-derived xenograft mouse models.
Nat Rev Cancer. 15:311–316. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson JI, Decker S, Zaharevitz D,
Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M,
Arbuck S, Hollingshead M and Sausville EA: Relationships between
drug activity in NCI preclinical in vitro and in vivo models and
early clinical trials. Br J Cancer. 84:1424–1431. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hidalgo M, Bruckheimer E, Rajeshkumar NV,
Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick
MJ, Martell J and Sidransky D: A pilot clinical study of treatment
guided by personalized tumorgrafts in patients with advanced
cancer. Mol Cancer Ther. 10:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stanley RH: Molecular pathology. Mol
Oncol. 6:177–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verweij J, de Jonge M, Eskens F and
Sleijfer S: Moving molecular targeted drug therapy towards
personalized medicine: Issues related to clinical trial design. Mol
Oncol. 6:196–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garay JP and Gray JW: Omics and therapy-A
basis for precision medicine. Mol Oncol. 6:128–139. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chakradhar S: Colorectal cancer: 5 big
questions. Nature. 521:S162015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Macconaill LE and Garraway LA: Clinical
implications of the cancer genome. J Clin Oncol. 28:5219–2528.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Belchis DA, Tseng LH, Gniadek T, Haley L,
Lokhandwala P, Illei P, Gocke CD, Forde P, Brahmer J, Askin FB, et
al: Heterogeneity of resistance mutations detectable by
next-generation sequencing in TKI-treated lung adenocarcinoma.
Oncotarget. 7:45237–45248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jee J, Rasouly A, Shamovsky I, Akivis Y,
Steinman SR, Mishra B and Nudler E: Rates and mechanisms of
bacterial mutagenesis from maximum-depth sequencing. Nature.
534:693–696. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woollard PM, Mehta NA, Vamathevan JJ, Van
Horn S, Bonde BK and Dow DJ: The application of next-generation
sequencing technologies to drug discovery and development. Drug
Discov Today. 16:512–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guan Z, Lan H, Chen X, Jiang X, Wang X and
Jin K: Individualized drug screening based on next generation
sequencing and patient derived xenograft model for pancreatic
cancer with bone metastasis. Mol Med Rep. 16:4784–4790. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Zhang L, Su X, Li M, Xie L,
Malchers F, Fan S, Yin X, Xu Y, Liu K, et al: Translating the
therapeutic potential of AZD4547 in FGFR1-amplified non-small cell
lung cancer through the use of patient-derived tumor xenograft
modes. Clin Cancer Res. 18:6658–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shteyngart B, Chaiwiriyakul S, Wong J and
Cantor JO: Preferential binding of lysozyme to elastic fibres in
pulmonary emphysema. Thorax. 53:193–196. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Zhu LX, Cheng X, Lin Y, Yan P and
Peng B: Promotion of dental pulp cell migration and pulp repair by
a bioceramic putty involving FGFR-mediated signaling pathways. J
Dent Res. 94:853–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garralda E, Paz K, López-Casas PP, Jones
S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez
D, et al: Integrated next-generation sequencing and avatar mouse
models for personalized cancer treatment. Clin Cancer Res.
20:2476–2484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Katoh M and Nakagama H: FGF receptors:
Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gavine PR, Mooney L, Kilgour E, Thomas AP,
Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et
al: AZD4547: An orally bioavailable, potent, and selective
inhibitor of the fibroblast growth factor receptor tyrosine kinase
family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lehnen NC, von Mässenhausen A, Kalthoff H,
Zhou H, Glowka T, Schütte U, Höller T, Riesner K, Boehm D,
Merkelbach-Bruse S, et al: Fibroblast growth factor receptor 1 gene
amplification in pancreatic ductal adenocarcinoma. Histopathology.
63:157–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
